Minimum Order Quantities Vary By Product
đźšš Save BIG on Truckload orders!
Let me tell you about a pharmaceutical manufacturer that discovered their “approved” supplier couldn’t provide required documentation—after they’d already received $3.6 million in materials.
They produced pharmaceutical tablets requiring specialized packaging including bulk bags for API handling and drum liners for excipient storage. They’d qualified a new supplier through standard procurement process. Basic documentation reviewed. Supplier approved. Materials ordered and delivered.
Then their pharmaceutical quality assurance team attempted to release materials for production use. The QA manager requested complete pharmaceutical documentation package for manufacturing release. The supplier’s response was devastating: “We provided certificate of analysis with shipment. What other documentation do you need?”
The QA manager explained pharmaceutical documentation requirements. The supplier’s response: “We don’t have that level of documentation. We’re an industrial supplier—we provided standard industrial documentation. If you need pharmaceutical documentation, that wasn’t communicated during qualification.”
The nightmare scenario: $3.6M pharmaceutical packaging materials on-site but unable to be released for production. Missing: material validation data, extractables testing, complete compositional analysis, change control documentation, traceability to raw material specifications, pharmaceutical-grade certificates of analysis.
Materials couldn’t be used without documentation. Materials couldn’t be returned (custom specifications). Production schedules disrupted. Customer deliveries delayed. Emergency documentation remediation required 12-16 weeks. Estimated total cost: $8.4M (material write-off + production disruption + customer penalties + remediation costs).
Root cause: Procurement never defined pharmaceutical documentation requirements to supplier. Supplier provided standard industrial documentation adequate for non-pharmaceutical but insufficient for pharmaceutical production release. Gap discovered after materials received and supplier approved.
A pharmaceutical packaging consultant restructured their supplier qualification documentation requirements—creating comprehensive pharmaceutical documentation specification communicated BEFORE supplier selection, verified during qualification, tested during trial production, formally required in quality agreement.
Here’s what pharmaceutical manufacturers need to understand: pharmaceutical packaging requires 8 categories of documentation beyond industrial standards—failure to specify requirements creates production disasters.
So when someone asks “what documents should a pharma packaging supplier provide,” they’re really asking: what 8 pharmaceutical documentation categories enable cGMP-compliant material release?
Category 1: Lot Release Documentation (Every Shipment)
Documentation required with EVERY pharmaceutical packaging material shipment:
Pharmaceutical Certificate Of Analysis (COA):
Critical COA Elements (Beyond Industrial COA):
Unique lot/batch number with supplier prefix. Manufacturing date AND expiration date (if applicable). Complete test results for EVERY specification parameter (not “typical values”). Actual numeric results with units (not just “Pass/Fail”). Specification limits showing actual results within range. Test methods identified by validated method number. Raw material lot traceability (identifying source lots). Manufacturing site identifier (critical for multi-site suppliers). QA release signature with authority confirmation. cGMP compliance statement. Unique COA document control number. Issue date and version (if COA revised).
Pharmaceutical COA Example: Product: Polyethylene Drum Liner, 55-Gallon Lot Number: CPP-DL-240156 Manufacturing Date: January 15, 2024 Test Parameter | Specification | Result | Method Thickness: 6.0 ± 0.5 mil | 6.2 mil | TM-003 Tensile Strength: ≥3000 psi | 3,240 psi | ASTM D882 Dart Impact: ≥300 g | 325 g | ASTM D1709 Raw Material Lot: RM-PE-240012 (Virgin LLDPE) Manufacturing Site: Conroe, TX (Site Code: TX-01) QA Release: [Signature] John Smith, QA Manager, 1/18/2024 cGMP Compliance: Materials manufactured under cGMP COA Number: COA-2024-00156
Industrial COA Problems: Generic results without lot specificity. “Typical values” not actual test results. Missing raw material traceability. No manufacturing site identification. Missing cGMP compliance statement. No QA release signature authority. Inadequate for pharmaceutical release.
Certificate Of Conformance:
Conformance Statement Requirements: Material conforms to approved specification (with specification document reference). Manufactured per approved manufacturing procedures. Raw materials meet approved specifications. Manufacturing facility operating under cGMP. No deviations from standard manufacturing occurred (or deviations documented and justified). Material released by Quality Assurance.
Packing List With Pharmaceutical Detail:
Lot number prominently displayed. Quantity with clear units. Purchase order and line item reference. Expiration date (if applicable). Storage condition requirements. Handling requirements (if special). “Inspect upon receipt” reminder. Supplier contact for quality questions.
Material Safety Data Sheet (Current):
SDS dated within last 3 years. Matches specific material lot. Emergency contact information. Proper GHS classifications. Pharmaceutical-appropriate handling information.
Call or Text us at 832.400.1394 for a Quote!
Category 2: Material Master Documentation (Initial Qualification)
One-time documentation establishing material for pharmaceutical use:
Master Specification Document:
Complete Material Specification: Material description and intended use. Chemical name and CAS number (if applicable). Physical form and appearance. ALL quality attributes with specifications. Test methods for each attribute (with method references). Acceptance criteria (numerical ranges). Sampling plans and procedures. Reference standards used. Specification effective date and version control. Specification approval signatures.
Material Composition And Formula:
Detailed Compositional Information: Complete material composition (all components >0.1%). Raw material specifications for each component. Supplier information for critical raw materials. Processing aids and additives. Colorants and their specifications. Regulatory status of ALL components. Absence of animal-derived materials statement (if applicable). Absence of latex statement (if applicable).
Extractables And Leachables Data:
For Direct Product Contact Materials: Extractables study protocol and results. Leachables risk assessment. Testing under relevant conditions (solvents, temperatures). Identification of extracted compounds. Quantification of extractables. Safety assessment of extractables. Comparison to safety thresholds. Study report with conclusions.
Material Stability Data:
Stability Information: Storage stability under specified conditions. Expiration date justification (if applicable). Stability protocol and results. Real-time and accelerated data. Stability-indicating tests. Retest date recommendations (if no expiration).
Regulatory Status Documentation:
Compendial Conformance (Where Applicable): USP monograph conformance (if USP material). EP monograph conformance (if EP material). JP conformance (if Japan business). Certificates of suitability (CEP) if applicable.
FDA Regulatory Compliance: 21 CFR compliance (if food/drug contact). Drug Master File number (if DMF exists). FDA establishment registration (if applicable). Regulatory compliance letter.
Category 3: Manufacturing Documentation
Documentation describing material manufacturing:
Manufacturing Process Description:
Process flow diagram. Critical process parameters and ranges. In-process controls and acceptance criteria. Environmental controls (temperature, humidity, cleanliness). Equipment used in manufacturing. Process capability data.
Process Validation Summary:
Validation protocol overview. Validation acceptance criteria. Validation results summary. Revalidation frequency. Process performance monitoring.
Cleaning Validation (If Applicable):
Cleaning procedures for shared equipment. Cleaning validation protocol and results. Residue limits and detection methods. Cleaning effectiveness verification. Applicable for multi-product facilities.
Category 4: Quality System Documentation
Documentation verifying pharmaceutical quality systems:
Pharmaceutical Certification:
ISO 15378 certificate (pharmaceutical packaging specific). Certification body accreditation verification. Certificate scope covering your materials. Current valid certificate (not expired).
cGMP Compliance Documentation:
cGMP compliance attestation. Quality manual (or relevant sections). Validation policy. Change control procedures. Deviation management procedures. CAPA (corrective/preventive action) procedures. Document control procedures. Training procedures.
Supplier Qualification Documentation:
Supplier approval procedures. Raw material specifications. Incoming material testing. Supplier performance monitoring. Supply chain control documentation.
Category 5: Traceability Documentation
Documentation enabling complete lot traceability:
Forward Traceability:
From raw materials through manufacturing to finished lot. Raw material lot numbers used in each finished lot. Manufacturing records linking lots. Distribution records to customers. Complete chain without gaps.
Backward Traceability:
From finished lot back to raw material lots. Manufacturing date and location. Equipment used. Personnel involved. Environmental conditions. Complete documentation trail.
Traceability Capability Demonstration:
Traceability time commitment (24-48 hours maximum). Mock recall exercise results. Traceability test during qualification. Complete documentation package provided within committed time.
Category 6: Change Control Documentation
Documentation when ANY changes occur:
Change Notification Requirements:
Changes Requiring Customer Notification BEFORE Implementation: Material composition changes. Manufacturing process changes. Manufacturing site changes. Raw material supplier changes. Specification changes. Test method changes. Quality system changes affecting material. Equipment changes (major).
Change Control Package:
Change description and justification. Impact assessment on material quality. Risk assessment. Revalidation requirements (if needed). Regulatory assessment. Customer approval form. Effective date and affected lots. Communication plan.
Change Control Red Flags:
Changes implemented WITHOUT customer notification. Changes notified AFTER implementation. Inadequate impact assessment. No revalidation when required. Vague change descriptions. Missing effective dates.
Category 7: Audit And Compliance Documentation
Documentation supporting ongoing compliance:
Internal Audit Reports:
Recent internal audit schedule and scope. Audit findings and observations. Corrective actions implemented. Effectiveness verification. Demonstrates quality system functioning.
External Certification Audits:
Recent certification audit reports (summary). Non-conformances and corrective actions. Continuous improvement initiatives. Certification maintenance status.
Regulatory Inspection History:
FDA inspection history (if applicable). Warning letters or 483 observations (MUST disclose). Corrective actions for regulatory findings. Current compliance status. Consent decrees or legal agreements (MUST disclose).
Customer Audit Reports:
Recent customer audit findings. Corrective actions implemented. Open CAPA items status. Demonstrates transparency and improvement.
Quality Performance Metrics:
Defect rates and trending. Customer complaint rates. On-time delivery performance. Right-first-time manufacturing. Demonstrates continuous improvement.
Category 8: Deviation And Investigation Documentation
Documentation when problems occur:
Non-Conformance Reports:
Non-conformance description. Affected lots identified. Impact assessment (which customers/lots affected). Root cause analysis. Immediate containment actions. Corrective actions (short and long term). Preventive actions. Effectiveness verification. Timeline for actions.
Out-Of-Specification (OOS) Investigations:
OOS result description. Investigation protocol. Laboratory investigation results. Manufacturing investigation results. Root cause determination. Material disposition decision (release, reject, rework). CAPA implementation. Regulatory notification (if required).
Customer Complaint Investigation Reports:
Complaint description and date received. Investigation findings and timeline. Root cause analysis. Impact assessment (other lots affected?). Corrective actions implemented. Effectiveness verification. Customer communication log. Closure documentation.
Recall Or Field Action Reports:
Issue requiring recall/field action. Affected lot numbers and quantities. Customers affected and notification. Root cause analysis. Corrective actions to prevent recurrence. Regulatory notifications (FDA, EMA, etc.). Effectiveness checks. Recall completion documentation.
Documentation Delivery And Format Requirements
Electronic Documentation Systems:
Secure portal access preferred. Electronic COA delivery with shipment. Version control and audit trails. 21 CFR Part 11 compliance (if electronic signatures). Backup and disaster recovery. Search and retrieval capability.
Delivery Timing:
Routine documentation: With or before shipment. Qualification documentation: During qualification process. Change notifications: BEFORE change implementation (minimum 60-90 days for assessment). Investigation reports: Within 30 days of investigation completion.
Documentation Retention:
Supplier retention: Minimum 5 years post-shipment. Longer retention for validation documentation. Electronic archiving with retrieval capability. Retention per cGMP requirements.
What Complete Pharma Packaging Documentation Includes
âś“ Category 1: Lot release documentation (COA, conformance, SDS) with every shipment âś“ Category 2: Material master documentation (specifications, composition, extractables, stability, regulatory) âś“ Category 3: Manufacturing documentation (process, validation, cleaning) âś“ Category 4: Quality system documentation (ISO 15378, cGMP, supplier qualification) âś“ Category 5: Traceability documentation (24-48 hour forward/backward capability) âś“ Category 6: Change control documentation (notification BEFORE changes) âś“ Category 7: Audit/compliance documentation (inspections, metrics, improvement) âś“ Category 8: Deviation/investigation documentation (non-conformances, OOS, complaints, recalls)
Complete pharmaceutical documentation package enables cGMP-compliant material release and ongoing compliance.
Stop Discovering Documentation Gaps After Material Receipt
Your pharmaceutical operation cannot afford discovering documentation inadequacy after receiving $3-4M materials—creating production delays, material write-offs, and compliance risks.
Custom Packaging Products provides complete pharmaceutical documentation packages—pharmaceutical-grade COAs, validation support, traceability capability, change control, compliance documentation.
Partner with the pharmaceutical documentation specialist since 1973.